Transplant study for Medicare patients with advanced myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at outcomes of an allogeneic transplant (a donor-based transplant) in people with stage II–III multiple myeloma or primary plasma cell leukemia who have Medicare. It may help doctors better understand which patients benefit and what to expect before and after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Medicare health coverage.
- You have stage II or stage III multiple myeloma and/or primary plasma cell leukemia.
- Your transplant center says you are eligible for a donor transplant (an allogeneic HCT), possibly including umbilical cord blood.
- Your transplant would be done at a transplant center in the United States.
- You agree to share detailed health information about your condition before and after transplant with the CIBMTR.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
This study is a registry that tracks outcomes for adults with blood diseases (such as leukemia, lymphoma, or severe aplastic anemia) who receive a haploidentical stem cell transplant—a transplant from a half-matched donor. The goal is to gather real-world data to understand how well this approach works for people who do not have a fully matched donor.
This Phase 2 trial tests whether adding isatuximab and lenalidomide as long-term treatment after stem cell transplant can help keep high-risk multiple myeloma under control. It may help some people reduce the chance of the disease coming back after transplant.
This study combines a stem cell transplant with a special immune therapy (CAR-T) to treat multiple myeloma that is very aggressive and has not responded well to initial treatments. The goal is to see if this combination can better control the cancer.
This trial looks at people with newly diagnosed multiple myeloma who have no detectable cancer cells after initial treatment. It aims to see if these patients can do well without a stem cell transplant or with a delayed one, reducing unnecessary side effects.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.